

LigaSure™ Exact vessel sealing

Proven performance. A variety of procedures.

Trust in the confident vessel sealing of LigaSure™ Exact technology – advancing patient care with globally documented^{1,2} reliable performance.



LigaSure™
Exact dissector

Used for
breast surgery procedures:

21 published references²

11 countries^{2,†}

Backed by >25 years
of research and development

Used in more than
35 million procedures¹

[†] LigaSure™ Exact is the only LigaSure™ device cleared in the United States for breast procedures.

Clinical and economic benefits for breast surgery

Operative time

Use of LigaSure™ Exact technology achieves:

- Shorter surgical time compared to conventional methods³⁻¹²
- Equivalent operative time compared to other advanced energy devices⁴

Postprocedural drainage

When compared with conventional ligation, LigaSure™ Exact devices are shown to:

- Decrease drainage duration³⁻¹¹
- Reduce drainage volume^{3-11,13}

The costs of complications

Complications related to breast surgery can be expensive, increasing total treatment costs by up to \$10,000 per patient^{14,15} or up to 44%.¹⁵ Increased safety and efficiency during breast procedures can potentially minimize the risk of complications and provide economic benefits.

With a comparable safety profile,^{3,4,6-8,10,11,13,16,†} shorter surgical times,^{3-12,†} and reduced drainage duration and volume,^{3-11,13,†} you can depend on LigaSure™ Exact devices to provide this safety and efficiency.

**Trusted confidence.
Clear clinical value.**

Ready to bring the benefits of
LigaSure™ Exact technology
to your OR?

Contact your local Medtronic
sales representative today.

Medtronic

©2025 Medtronic. All rights reserved. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company.
emea-se-2500025-ligasure-exact-device-breasts-facts-infographic---17865123

[medtronic.com/covidien/uk](https://www.medtronic.com/covidien/uk)

† Compared to conventional ligation.

1. Based on internal sales data from FY01-FY24, November 2023.
2. Based on report #US-SE-2200114, Global value dossier for LigaSure™ Exact technology – Breast surgery (version no. 1.0). October 2022.
3. Cortadellas T, Córdoba O, Espinosa-Bravo M, et al. Electrothermal bipolar vessel sealing system in axillary dissection: a prospective randomized clinical study. *Int J Surg*. 2011;9(8):636-640. doi:10.1016/j.ijssu.2011.08.002.
4. Gambardella C, Clarizia G, Patrone R, et al. Advanced hemostasis in axillary lymph node dissection for locally advanced breast cancer: new technology devices compared in the prevention of seroma formation. *BMC Surg*. 2019;18(Suppl 1):125. doi:10.1186/s12893-018-0454-8.
5. Inoue Y, Yamashita N, Ueo H, et al. The Clinical Usefulness of the LigaSure™ Small Jaw in Axillary Lymph Node Dissection in Patients with Breast Cancer. *Anticancer Res*. 2018;38(4):2359-2362. doi:10.21873/anticancer.12483.
6. Nespoli L, Antolini L, Stucchi C, Nespoli A, Valsecchi MG, Gianotti L. Axillary lymphadenectomy for breast cancer. A randomized controlled trial comparing a bipolar vessel sealing system to the conventional technique. *Breast*. 2012;21(6):739-745. doi:10.1016/j.breast.2012.08.003.
7. Pergialiotis V, Kontzoglou K, Dimitroulis D, Vlachos D-EG, Routsolias P, Vlachos GD. Electrosurgical bipolar vessel sealing during axillary lymphadenectomy: a systematic review and meta-analysis. *Breast Dis*. 2015;35(1):5-11. doi:10.3233/BD-140383.
8. Seki T, Hayashida T, Takahashi M, Jinno H, Kitagawa Y. A randomized controlled study comparing a vessel sealing system with the conventional technique in axillary lymph node dissection for primary breast cancer. *Springerplus*. 2016;5(1):1004. doi:10.1186/s40064-016-2710-7.
9. Tukenmez M, Agcaoglu O, Aksakal N, et al. The use of Ligasure vessel sealing system in axillary dissection; effect on seroma formation. *Chirurgia (Bucur)*. 2014;109(5):620-625.
10. Lee JS, Kim DG, Lee JW, et al. Usefulness of the LigaSure™ small jaw sealing device for breast reconstruction with a latissimus dorsi flap. *J Plast Surg Hand Surg*. 2019;53(5):295-300. doi:10.1080/2000656X.2019.1612753.
11. Chang YW, Kim HS, Jung SP, et al. Comparison of skin-sparing mastectomy using LigaSure™ Small Jaw and electrocautery. *World J Surg Oncol*. 2017;15(1):129. doi:10.1186/s12957-017-1199-z.
12. Hirano J, Kinoshita S, Kazama T, et al. Value of Vessel Sealing System in Skin-Sparing Mastectomy in Patients with Early Breast Cancer. *Clinics in Surgery*. 2018;3(1).
13. Kim MK, Lee S. LigaSure for the Creation of Bloodless Breast Pockets in Patients Undergoing Transaxillary Breast Augmentation. *Plast Reconstr Surg Glob Open*. 2020;8(12):e3295. doi:10.1097/GOX.0000000000003295.
14. Smith BD, Jiang J, Shih Y-C, et al. Cost and Complications of Local Therapies for Early-Stage Breast Cancer. *J Natl Cancer Inst*. 2017;109(1). doi:10.1093/jnci/djw178.
15. Kouwenberg CAE, Mureau MAM, Kranenburg LW, et al. Cost-utility analysis of four common surgical treatment pathways for breast cancer. *Eur J Surg Oncol*. 2021;47(6):1299-1308. doi:10.1016/j.ejso.2020.11.130.
16. Panhofer P, Rothe S, Schütz M, et al. Morbidity reduction using the vessel sealing device LigaSure™ in breast cancer surgery. *Eur Surg*. 2015;47(4):150-156. doi:10.1007/s10353-015-0334-8.

This material should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s).

Please note that the intended use of a product may vary depending on geographical approvals.

See the device manual(s) for detailed information regarding the intended use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events.

If a device is eligible for eIFU usage, instructions for use can be found at Medtronic's website manuals.medtronic.com.

Medtronic products placed on European markets bear the CE mark and the UKCA mark (if applicable).

For any further information, contact your local Medtronic representative and/or consult Medtronic's websites.